Pacific Edge Limited (PFGTF) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Pacific Edge Limited, a leader in cancer diagnostics, announced a steady financial performance for the first half of 2024, despite uncertainties surrounding Medicare. The company is anticipating potential growth catalysts, including a favorable Medicare policy decision and new pricing recommendations for its Cxbladder tests. While revenue slightly declined compared to the previous year, the strategic focus remains on profitable markets and the economic value of its diagnostic tools.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Paramount (NASDAQ:PARA) Reduces Its Macy’s Thanksgiving Parade Connection
- Ford (NYSE:F) Slides as Trump Threatens to Hit Mexico with Tariffs
- Intel’s (NASDAQ:INTC) CHIPS Act Payout Will Be $7.87 Billion
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
